StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)

Posted by on Jun 5th, 2023

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

APTO has been the topic of a number of other reports. Canaccord Genuity Group decreased their price target on Aptose Biosciences from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Aptose Biosciences in a research report on Friday, March 24th.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.43 on Monday. Aptose Biosciences has a 12-month low of $0.36 and a 12-month high of $1.03. The company has a 50 day moving average of $0.51 and a 200-day moving average of $0.59. The firm has a market cap of $39.97 million, a P/E ratio of -0.90 and a beta of 1.53.

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) last posted its earnings results on Thursday, March 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). During the same quarter in the previous year, the company posted ($0.27) earnings per share. As a group, equities analysts expect that Aptose Biosciences will post -0.5 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank lifted its holdings in shares of Aptose Biosciences by 80.4% in the 3rd quarter. Toronto Dominion Bank now owns 43,851 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 19,541 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Aptose Biosciences during the 1st quarter worth $27,000. Cetera Advisors LLC lifted its stake in shares of Aptose Biosciences by 40.1% during the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 24,847 shares during the last quarter. Formidable Asset Management LLC acquired a new position in shares of Aptose Biosciences during the fourth quarter worth $52,000. Finally, Callan Capital LLC purchased a new stake in Aptose Biosciences in the fourth quarter valued at about $91,000. Hedge funds and other institutional investors own 26.60% of the company’s stock.

Aptose Biosciences Company Profile

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Stories

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.